Jasper Therapeutics Reports Positive Phase 1b Study Results

Jasper Therapeutics ( (JSPR) ) has provided an announcement.

On December 2, 2025, Jasper Therapeutics announced positive preliminary clinical data from its ETESIAN Phase 1b study, showing that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and eosinophilic response in adult participants with allergic asthma. The study supports further development of briquilimab as a potential therapeutic option for asthma patients. Additionally, Jasper completed an internal investigation into the lack of clinical response in the July 2025 BEACON study, concluding that the unexpected results were due to patient selection issues rather than problems with the drug product.

The most recent analyst rating on (JSPR) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

Average Trading Volume: 422,135

Technical Sentiment Signal: Sell

Current Market Cap: $48.13M

For an in-depth examination of JSPR stock, go to TipRanks’ Overview page.